Skip to content
Open access

CAR-T Therapy in Leukemia: Limitations and Prospects

Oct 2026 · Theoretical and Natural Science · 0 citations

Abstract

In the broad field of cancer management via immunotherapy, chimeric antigen receptor T-cell therapy (CAR-T therapy), commonly known as CAR-T therapy, has become a game-changing approach, particularly for patients with relapsed or refractory lymphoma. Using genetic engineering, a patient's T cells can be genetically modified to target specific tumor antigens allowing CAR-T cells to identify and destroy abnormal cells, which can provide long-term anti-tumor responses. The mechanisms and clinical applications of CAR-T therapy in leukemia, particularly in B-cell ALL and CD19-targeted CAR-T therapy will be discussed in this thesis. While CAR-T therapy shows great promise in its therapeutic ability, it faces a number of critical challenges, including insufficient efficacy against solid malignancies, on-target off-tumor effects, cytokine release syndrome (CRS), and the cost and complexity of individualized production. To overcome these issues, investigators have investigated innovations aimed at enhancing CAR-T cell stability, infiltration into tumors, and anti-tumor efficacy, such as the creation of IL-7/XCL1-armed CAR-T cells. Additionally, outcome-based reimbursement programs could help to reduce some of the financial barriers associated with CAR-T treatment. To conclude, CAR-T therapy represents a potential breakthrough in lymphoma treatment, while continued research into safety, persistence, accessibility, and cost-effectiveness is crucial to further improve the medical benefits.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.